Neuren Files Updated ASX Governance Appendix, Confirms Compliance With Key Standards

Neuren Pharmaceuticals Limited ( (AU:NEU) ) just unveiled an update.

Neuren Pharmaceuticals has lodged its Appendix 4G and confirmed that its corporate governance statement for the year ended 31 December 2025 is included in its latest annual report and current as of 31 March 2026. The filing, authorised by CFO and Company Secretary Lauren Frazer, affirms that the company follows the ASX Corporate Governance Council’s key recommendations, including a formal board charter, director vetting and written agreements for directors and executives.

The disclosures indicate that Neuren’s company secretary reports directly to the board through the chair, reinforcing the board’s oversight of governance processes. By mapping where each governance disclosure can be found, the Appendix 4G serves as both a transparency tool for investors and a compliance check, underscoring Neuren’s adherence to ASX listing rules and established governance standards.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.10 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited is a biopharmaceutical company focused on developing therapies for neurological disorders. Listed on the ASX, it operates under Australian corporate governance requirements and reports annually on its governance practices to investors and regulators.

Average Trading Volume: 540,264

Technical Sentiment Signal: Sell

Current Market Cap: A$1.57B

For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.